Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects
Study Identifier:
C11-002
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Other
Study Drug
- Drug: ALXN1007
Date
Nov 2011 - Aug 2013
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 25 - 55 Years
Requirements Information
Sex
Female & Male
Age
25 - 55 Years
Study Details
Medical Condition
- Other
Study Drug
- Drug: ALXN1007
Date
Nov 2011 - Aug 2013
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 25 - 55 Years years
Requirements Information
Protocol Summary
The purpose of the study is to evaluate the safety, tolerability, PK and PD of a single-dose of ALXN1007 in healthy volunteers.
Trial Locations
Location
Status
Location
PAREXEL Baltimore EPCU
Baltimore, Maryland, United States, 21225
Status
N/A